Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 1
2016 8
2017 5
2018 11
2019 8
2020 10
2021 8
2022 4
2023 4
2024 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

56 results

Results by year

Filters applied: . Clear all
Page 1
ORY-1001, a Potent and Selective Covalent KDM1A Inhibitor, for the Treatment of Acute Leukemia.
Maes T, Mascaró C, Tirapu I, Estiarte A, Ciceri F, Lunardi S, Guibourt N, Perdones A, Lufino MMP, Somervaille TCP, Wiseman DH, Duy C, Melnick A, Willekens C, Ortega A, Martinell M, Valls N, Kurz G, Fyfe M, Castro-Palomino JC, Buesa C. Maes T, et al. Cancer Cell. 2018 Mar 12;33(3):495-511.e12. doi: 10.1016/j.ccell.2018.02.002. Epub 2018 Mar 1. Cancer Cell. 2018. PMID: 29502954 Free article.
Addition of Navitoclax to Ongoing Ruxolitinib Therapy for Patients With Myelofibrosis With Progression or Suboptimal Response: Phase II Safety and Efficacy.
Harrison CN, Garcia JS, Somervaille TCP, Foran JM, Verstovsek S, Jamieson C, Mesa R, Ritchie EK, Tantravahi SK, Vachhani P, O'Connell CL, Komrokji RS, Harb J, Hutti JE, Holes L, Masud AA, Nuthalapati S, Potluri J, Pemmaraju N. Harrison CN, et al. J Clin Oncol. 2022 May 20;40(15):1671-1680. doi: 10.1200/JCO.21.02188. Epub 2022 Feb 18. J Clin Oncol. 2022. PMID: 35180010 Free PMC article. Clinical Trial.
Targeting the RNA m6A Reader YTHDF2 Selectively Compromises Cancer Stem Cells in Acute Myeloid Leukemia.
Paris J, Morgan M, Campos J, Spencer GJ, Shmakova A, Ivanova I, Mapperley C, Lawson H, Wotherspoon DA, Sepulveda C, Vukovic M, Allen L, Sarapuu A, Tavosanis A, Guitart AV, Villacreces A, Much C, Choe J, Azar A, van de Lagemaat LN, Vernimmen D, Nehme A, Mazurier F, Somervaille TCP, Gregory RI, O'Carroll D, Kranc KR. Paris J, et al. Cell Stem Cell. 2019 Jul 3;25(1):137-148.e6. doi: 10.1016/j.stem.2019.03.021. Epub 2019 Apr 25. Cell Stem Cell. 2019. PMID: 31031138 Free PMC article.
A KRAS-responsive long non-coding RNA controls microRNA processing.
Shi L, Magee P, Fassan M, Sahoo S, Leong HS, Lee D, Sellers R, Brullé-Soumaré L, Cairo S, Monteverde T, Volinia S, Smith DD, Di Leva G, Galuppini F, Paliouras AR, Zeng K, O'Keefe R, Garofalo M. Shi L, et al. Nat Commun. 2021 Apr 1;12(1):2038. doi: 10.1038/s41467-021-22337-3. Nat Commun. 2021. PMID: 33795683 Free PMC article.
Transcriptional control of blood cell emergence.
Menegatti S, de Kruijf M, Garcia-Alegria E, Lacaud G, Kouskoff V. Menegatti S, et al. FEBS Lett. 2019 Dec;593(23):3304-3315. doi: 10.1002/1873-3468.13585. Epub 2019 Aug 31. FEBS Lett. 2019. PMID: 31432499 Free PMC article. Review.
POTEE promotes breast cancer cell malignancy by inducing invadopodia formation through the activation of SUMOylated Rac1.
Martínez-López A, García-Casas A, Infante G, González-Fernández M, Salvador N, Lorente M, Mendiburu-Eliçabe M, Gonzalez-Moreno S, Villarejo-Campos P, Velasco G, Malliri A, Castillo-Lluva S. Martínez-López A, et al. Mol Oncol. 2024 Mar;18(3):620-640. doi: 10.1002/1878-0261.13568. Epub 2023 Dec 27. Mol Oncol. 2024. PMID: 38098337 Free PMC article.
56 results